Loading market dashboard
Vertex, Inc.
VERXTechnologyNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, pres.
Madrigal Pharmaceuticals, Inc. is a high-risk/high-reward play, focused solely on MASH with its first-in-class drug Rezdiffra. Rezdiffra's initial U.S. TAM is expanding, with diagnosis rates and label extensions potentially driving revenue to double-digit billions over the next decade. Competition from Novo Nordisk's Wegovy and upcoming Efruxifermin poses significant long-term risk, but MDGL enjoys a near-term lead and first-mover advantage.
VRTX moves closer to a potential nephrology launch as the FDA accepts its BLA for povetacicept in adults with IgAN, with a decision due in November 2026.
VRTX stock falls 7.9% in three months as Journavx and Casgevy sales missed expectations, but CF growth, Alyftrek momentum and renal pipeline progress stand out.
KING OF PRUSSIA, Pa., June 01, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), a leading provider of enterprise compliance technology for global commerce, today announced that Chris Young, President and Chief Executive Officer, and John Schwab, Chief Financial Officer, will present at the 46th Annual William Blair Growth Stock Conference on Wednesday, June 3, 2026 at 2:40 PM Central Time.
Only 12% of organizations globally have fully integrated tax technology, even as real-time compliance becomes business critical Only 12% of organizations globally have fully integrated tax technology, even as real-time compliance becomes business critical
Vertex NASDAQ: VERX reported first-quarter 2026 results above its guidance range and raised its full-year profitability outlook as management outlined a cost-reduction program intended to fund investments in e-invoicing, compliance and artificial intelligence.
Vertex remains a "Buy" as its tax compliance software business shows resilience amid broad SaaS sector weakness. Despite a ~20% YTD and 60% 1-year decline, VERX delivered a strong Q1 beat-and-raise, with accelerating growth and expanding margins. Fears of AI disruption are overblown for VERX, given the complexity and criticality of tax compliance, reinforcing its competitive moat.
Vertex, Inc. (VERX) Q1 2026 Earnings Call Transcript
While the top- and bottom-line numbers for Vertex (VERX) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Vertex (VERX) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.15 per share a year ago.
KING OF PRUSSIA, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading provider of enterprise compliance technology for global commerce, today announced financial results for its first quarter ended March 31, 2026.
Vertex Pharmaceuticals Incorporated delivered strong Q1 2026 earnings, with $2.99bn revenue and $4.02 EPS, but revenue growth is slowing as CF market saturates. VRTX's cystic fibrosis franchise remains dominant and highly profitable, but diversification efforts—Casgevy, Journavx, and povetacicept—face slow uptake or intense competition. Forward P/E of ~26.5x and P/S of ~8.3x are above Big Pharma averages, reflecting market concerns about future growth for VRTX beyond CF.
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that a reimbursement agreement was signed with the GKV-Spitzenverband for its CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). This agreement secures sustainable access to this innovative one-time treatment for eligible patients in Germany ages 12 years and older living with severe sickle cell disease or transfusion-dependent beta thalassemia. “For the first time in Germany, a long-t.
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reported mixed financial results for the first quarter after the market close on Monday.
Vertex Pharmaceuticals on Monday beat Wall Street estimates for first-quarter adjusted profit, helped by a near eight-fold surge in sales of its new cystic fibrosis treatment.
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2026, and reiterated its full year 2026 financial guidance. “Vertex is off to a strong start in 2026, driven by leadership in cystic fibrosis; growth in sickle cell disease, beta thalassemia, and acute pain; as well as rapid pipeline progress,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “CASGEVY and J.
VRTX heads into Q1 earnings with Trikafta demand, rising Alyftrek sales, and Casgevy and Journavx sales in focus ahead of the May 4 report.
On April 24, 2026, Vertex Inc (VERX) shares rose 7.2% today, currently trading at $12.52. The stock has fluctuated within a 52-week range of $10.59 to $42.44, r
Vertex Pharmaceuticals remains the leader in cystic fibrosis but is now executing a tangible diversification into pain, renal, and gene therapies. VRTX's CF franchise continues to grow via ALYFTREK's launch, geographic expansion, and penetration into younger and rare mutation populations, supporting robust revenue. New products JOURNAVX and CASGEVY are gaining traction, and the renal pipeline—especially povetacicept—could become a second franchise with multi-billion-dollar potential.
Vertex Pharmaceuticals' business will suffer if other drugmakers launch competing cystic fibrosis drugs. Despite this threat, Vertex Pharmaceuticals' core franchise looks safe for the foreseeable future.
KING OF PRUSSIA, Pa., April 13, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), a leading provider of enterprise compliance technology for global commerce, today announced that it will release first quarter 2026 financial results before the market opens on Thursday, May 7, 2026. A conference call to discuss the results will be held at 8:30 a.m. Eastern Time that same day.
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2026 financial results on Monday, May 4, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals First Quarter 2026 Earnings Call.” The conference call will be webcast live and a link to the webcast can be.
Aberdeen Group plc lessened its stake in Vertex, Inc. (NASDAQ: VERX) by 15.5% during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,221,776 shares of the company's stock after selling 224,058 shares during the quarter. Aberdeen Group plc owned approximately 0.77% of Vertex worth $24,399,000
Vertex, Inc. (NASDAQ: VERX - Get Free Report) has been given an average rating of "Hold" by the fifteen analysts that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and seven have given a buy recommendation to the company. The
Vertex Pharmaceuticals (VRTX) remains a "Strong Buy", driven by robust CF franchise growth and successful label expansions for ALYFTREK and TRIKAFTA. VRTX's new label expansions now cover 95% of U.S. CF patients, adding 800 eligible patients and supporting continued revenue growth. Positive phase 3 data for povetacicept in IgAN and ongoing regulatory submissions position VRTX for further diversification beyond CF.
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FD.
SAN DIEGO, March 25, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Vertex, Inc. (NASDAQ: VERX). The investigation focuses on Vertex's executive officers and whether investor losses may be recovered under federal securities laws.
Vertex (NASDAQ: VERX - Get Free Report) and UiPath (NYSE: PATH - Get Free Report) are both mid-cap computer and technology companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership. Volatility and Risk Vertex has a beta
VRTX stock slips nearly 5% as concerns over new drug uptake and pipeline setbacks weigh, even as its dominant CF franchise continues to drive steady growth.
Eli Lilly has strong momentum thanks to its leadership in the weight loss market. Vertex Pharmaceuticals' core franchise and newer approvals could drive top-line growth for a long time.
Bamco Inc. NY acquired a new stake in shares of Vertex, Inc. (NASDAQ: VERX) during the undefined quarter, according to its most recent 13F filing with the SEC. The firm acquired 248,042 shares of the company's stock, valued at approximately $6,149,000. Bamco Inc. NY owned 0.16% of Vertex at the end of the
The biotech company is the leader in the cystic fibrosis market and is quickly expanding into other treatment areas. Vertex forecasts its newer medicines may add $500 million to revenue this year.
Roofing Innovator Propels to Over $600M in Revenue with 30 Acquisitions in Three Years, Leveraging ServiceTitan's Enterprise-Grade Platform Roofing Innovator Propels to Over $600M in Revenue with 30 Acquisitions in Three Years, Leveraging ServiceTitan's Enterprise-Grade Platform
Vertex, Inc. (NASDAQ: VERX - Get Free Report) has received an average rating of "Hold" from the fifteen analysts that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and seven have assigned a buy recommendation to the company. The average
Reduced holding by 384,415 shares; estimated transaction value of $8.32 million based on quarterly average price Quarter-end position value decreased by $26.01 million, reflecting both share sales and price changes Represents a 1.08% shift in 13F reportable assets under management (AUM) Post-trade, the fund owns 3,419,994 shares, valued at $68.30 million The position now accounts for 8.85% of AUM, which places it outside the fund's top five holdings
Vertex Pharmaceuticals said its drug for a rare kidney condition succeeded in a Phase 3 trial. The drug, povetacicept, is a central piece of the company's plan to expand into kidney disease.
Vertex stock popped late Monday on promising test results for a drug that could treat a chronic autoimmune disease that destroys the kidneys.
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive data from a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). The trial met its primary objective. In the interim analysis population, patients treated with povetacicept ach.
Vertex (NASDAQ: VERX - Get Free Report) and i3 Verticals (NASDAQ: IIIV - Get Free Report) are both computer and technology companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, risk, institutional ownership, profitability, valuation and earnings. Institutional and Insider Ownership 70.3% of Vertex
